[Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a markers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up].
OBJECTIVE
The aim of our study was to determine the endothelial function in patients with chronic kidney disease (CKD), stage V (end-stage renal disease--ESRD), before and during a one-year observation after kidney allotransplantation.


METHODS
We studied 40 patients with stabile graft function after their first kidney transplantation, including 21 females (mean age 41 +/- 12.5 yrs) and 19 males (mean age 43.6 +/- 13.3 yrs), treated already with hemodialysis because of ESRD.


RESULTS
After transplantation we observed significant decrease in serum creatinine concentrations (Cr) (7.32 +/- 2.07 mg/dl to 1.50 +/- 0.45 mg/dl at 6 months and 1.61 +/- 0.58 mg/dl after 12 months after transplantation). During 12 months we found changes only in plasminogen activator inhibitor-1 (PAI-1) levels. Von Willebrandt factor (vWf) levels remained unaltered during follow-up and total homocysteine (tHcy) concentration decreased, but this change was not statistically significant. There was no correlation between vWf and PAI-1 concentrations and other clinical and laboratory findings.


CONCLUSIONS
In our study we did not find any improvement of endothelial function during the first year after kidney allotransplantation. The mean Cr concentration at the end of study was 1.6 mg/dl, which indicates the chronic kidney graft insufficiency. We conclude that despite kidney allotransplantation endothelial function is impaired like in CKD, but with more advanced abnormalities in the cardiovascular system.
Doroszewski
Witold
W
Katedra i Klinika Nefrologii, Nadciśnienia Tetniczego i Chorób Wewngtrznych, Collegium Medicum Uniwersytetu Mikołaja Kopernika, Bydgoszcz. nerka@nerka.cpro.pl
Włodarczyk
Zbigniew
Z
Strózecki
Paweł
P
Manitius
Jacek
J
Grabarczyk
Ewa
E
Rość
Danuta
D
Odrowaz-Sypniewska
Grazyna
G
D000328:Adult; D016022:Case-Control Studies; D003404:Creatinine / Q000097:blood*; D004730:Endothelium, Vascular / Q000378:metabolism*; D005260:Female; D006710:Homocysteine / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D013997:Time Factors; D014841:von Willebrand Factor / Q000032:analysis*
D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D006710:Homocysteine; D003404:Creatinine